Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03597295 · OUTCOME

Tmax of Retifanlimab

A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202) · Source last updated 2025-08-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
hours
Interval / dispersion
Standard Deviation
Time frame
pre-infusion on Day 1 of Cycles 1, 2, 4, 6, and 7; 10 minutes and 4 hours post-infusion on Day 1 of Cycles 1 and 6

What was measured

tmax was defined as the time to the maximum concentration.

Analysis population: PK Evaluable Population

Groups in this outcome

Retifanlimab 500 mg

Participants received retifanlimab 500 milligrams (mg) intravenously every 4 weeks (Q4W).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Retifanlimab 500 mg92

Reported measurements

Source class 1
Values in hours · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Retifanlimab 500 mg1.200.305Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.305
        value
        1.20
denoms
  1. counts
    1. group Id
      OG000
      value
      92
    units
    Participants
description
tmax was defined as the time to the maximum concentration.
dispersion Type
Standard Deviation
groups
  1. description
    Participants received retifanlimab 500 milligrams (mg) intravenously every 4 weeks (Q4W).
    id
    OG000
    title
    Retifanlimab 500 mg
param Type
MEAN
population Description
PK Evaluable Population
reporting Status
POSTED
time Frame
pre-infusion on Day 1 of Cycles 1, 2, 4, 6, and 7; 10 minutes and 4 hours post-infusion on Day 1 of Cycles 1 and 6
title
Tmax of Retifanlimab
type
SECONDARY
unit Of Measure
hours

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice